Neurocrine Biosciences is a biotechnology company focused on neurologic, psychiatric and endocrine-related disorders.The Company’s three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson’s patients; and INGREZZA™, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette Syndrome.Neurocrine utilizes advanced technologies to enhance its drug discovery capabilities and to accelerate the drug development process. Working together, Neurocrine’s chemists, pharmacologists, and biologists strive to create new solutions to unmet medical problems.